Chi Advisors LLC Corvus Pharmaceuticals, Inc. Transaction History

Chi Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.0 - $3.86 $2.14 Million - $8.26 Million	-2,139,402 Reduced 91.45%	200,000 $458,000
Q1 2023 May 11, 2023	SELL	$0.65 - $0.92 $29,250 - $41,400	-45,000 Reduced 1.89%	2,339,402 $2.13 Million
Q3 2022 Nov 09, 2022	BUY	$0.71 - $1.17 $120,854 - $199,155	170,218 Added 7.69%	2,384,402 $1.95 Million
Q2 2022 Aug 12, 2022	BUY	$0.87 - $2.03 $444,610 - $1.04 Million	511,047 Added 30.01%	2,214,184 $2.19 Million
Q1 2022 May 16, 2022	BUY	$1.46 - $2.48 $1.9 Million - $3.23 Million	1,303,137 Added 325.78%	1,703,137 $2.79 Million
Q4 2021 Feb 11, 2022	BUY	$2.34 - $5.31 $547,730 - $1.24 Million	234,073 Added 141.07%	400,000 $964,000
Q3 2021 Nov 15, 2021	SELL	$1.89 - $8.53 $1.05 Million - $4.72 Million	-553,205 Reduced 76.93%	165,927 $803,000
Q2 2021 Aug 11, 2021	BUY	$2.46 - $3.14 $98,400 - $125,600	40,000 Added 5.89%	719,132 $1.92 Million
Q1 2021 May 14, 2021	BUY	$2.86 - $4.77 $538,409 - $897,976	188,255 Added 38.35%	679,132 $2.09 Million
Q4 2020 Feb 12, 2021	SELL	$3.56 - $4.86 $328,783 - $448,845	-92,355 Reduced 15.84%	490,877 $1.75 Million
Q3 2020 Nov 12, 2020	BUY	$2.6 - $5.37 $569,660 - $1.18 Million	219,100 Added 60.17%	583,232 $2.34 Million
Q1 2020 May 14, 2020	SELL	$1.74 - $5.98 $10,744 - $36,926	-6,175 Reduced 1.67%	364,132 $768,000
Q4 2019 Feb 14, 2020	SELL	$2.56 - $5.44 $51,200 - $108,800	-20,000 Reduced 5.12%	370,307 $2.01 Million
Q3 2019 Nov 12, 2019	BUY	$3.01 - $6.5 $1.17 Million - $2.54 Million	390,307 New	390,307 $1.18 Million

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Chi Advisors LLC with notifications on news.